Glycosaminoglycan mimetic associated to human mesenchymal stem cell-based scaffolds inhibit ectopic bone formation, but induce angiogenesis in vivo

Tissue Engineering - Part A

Volumn 19, Issue 13-14, 2013, Pages 1641-1653

  Frescaline, Guilhem ^a   Bouderlique, Thibault ^a   Mansoor, Leyya ^a   Carpentier, Gilles ^a   Baroukh, Brigitte ^b   Sineriz, Fernando ^c   Trouillas, Marina ^d   Saffar, Jean Louis ^b   Courty, José ^a   Lataillade, Jean Jacques ^d   Papy Garcia, Dulce ^a   Albanese, Patricia ^a  

^a UNIVERSITÉ PARIS EST CRÉTEIL   (France)

^b France   (France)

^c OTR3 SAS   (France)

^d PERCY MILITARY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MATERIALS; BIOMATERIALS; BONE; HYDROXYAPATITE; STEM CELLS;

ECTOPIC BONE FORMATIONS; ENGINEERING APPROACHES; EXTRACELLULAR MATRICES; HEPARIN-BINDING PROTEINS; HUMAN MESENCHYMAL STEM CELLS; INFLAMMATORY RESPONSE; OSTEOGENIC DIFFERENTIATION; TRI-CALCIUM PHOSPHATES;

SCAFFOLDS (BIOLOGY);

MUS;

GLYCOSAMINOGLYCAN; TISSUE SCAFFOLD;

ANGIOGENESIS; ANIMAL; ARTICLE; CELL CULTURE; CHEMISTRY; CYTOLOGY; DRUG EFFECT; FEMALE; HUMAN; MESENCHYMAL STROMA CELL; METHODOLOGY; MOUSE; NUDE MOUSE; SCID MOUSE; TISSUE ENGINEERING; DRUG EFFECTS; PROCEDURES; TISSUE SCAFFOLD;

ANIMALS; CELLS, CULTURED; FEMALE; GLYCOSAMINOGLYCANS; HUMANS; MESENCHYMAL STROMAL CELLS; MICE; MICE, NUDE; MICE, SCID; NEOVASCULARIZATION, PHYSIOLOGIC; TISSUE ENGINEERING; TISSUE SCAFFOLDS;

EID: 84878419888     PISSN: 19373341     EISSN: 1937335X     Source Type: Journal    
DOI: 10.1089/ten.tea.2012.0377     Document Type: Article

References (52)

1. Carson, J.S., and Bostrom, M.P. Synthetic bone scaffolds and fracture repair. Injury 38 Suppl 1, S33, 2007.
2. Bielby, R., Jones, E., and McGonagle, D. The role of mesenchymal stem cells in maintenance and repair of bone. Injury 38 Suppl 1, S26, 2007.
3. Chevallier, N., Anagnostou, F., Zilber, S., Bodivit, G., Maurin, S., Barrault, A., et al. Osteoblastic differentiation of human mesenchymal stem cells with platelet lysate. Biomaterials 31, 270, 2010.
4. Ito, K., Yamada, Y., Nagasaka, T., Baba, S., and Ueda, M. Osteogenic potential of injectable tissue-engineered bone: a comparison among autogenous bone, bone substitute (Biooss), platelet-rich plasma, and tissue-engineered bone with respect to their mechanical properties and histological findings. J Biomed Mater Res A 73, 63, 2005.
5. Niemeyer, P., Krause, U., Kasten, P., Kreuz, P.C., Henle, P., Sudkam, N.P., et al. Mesenchymal stem cell-based HLAindependent cell therapy for tissue engineering of bone and cartilage. Curr Stem Cell Res Ther 1, 21, 2006.
6. Laschke, M.W., Harder, Y., Amon, M., Martin, I., Farhadi, J., Ring, A., et al. Angiogenesis in tissue engineering: breathing life into constructed tissue substitutes. Tissue Eng 12, 2093, 2006.
7. Grellier, M., Bordenave, L., and Amedee, J. Cell-to-cell communication between osteogenic and endothelial lineages: implications for tissue engineering. Trends Biotechnol 27, 562, 2009.
8. Roldan, J.C., Detsch, R., Schaefer, S., Chang, E., Kelantan, M., Waiss, W., et al. Bone formation and degradation of a highly porous biphasic calcium phosphate ceramic in presence of BMP-7, VEGF and mesenchymal stem cells in an ectopic mouse model. J Craniomaxillofac Surg 38, 423, 2010.
9. Chen, F.M., Zhang, M., and Wu, Z.F. Toward delivery of multiple growth factors in tissue engineering. Biomaterials 31, 6279, 2010.
10. Kim, S.H., Turnbull, J., and Guimond, S. Extracellular matrix and cell signalling: the dynamic cooperation of integrin, proteoglycan and growth factor receptor. J Endocrinol 209, 139, 2011.
11. Cool, S.M., and Nurcombe, V. Heparan sulfate regulation of progenitor cell fate. J Cell Biochem 99, 1040, 2006.
12. Dombrowski, C., Song, S.J., Chuan, P., Lim, X., Susanto, E., Sawyer, A.A., et al. Heparan sulfate mediates the proliferation and differentiation of rat mesenchymal stem cells. Stem Cells Dev 18, 661, 2009.
13. Manton, K.J., Leong, D.F., Cool, S.M., and Nurcombe, V. Disruption of heparan and chondroitin sulfate signaling enhances mesenchymal stem cell-derived osteogenic differentiation via bone morphogenetic protein signaling pathways. Stem Cells 25, 2845, 2007.
14. Handel, T.M., Johnson, Z., Crown, S.E., Lau, E.K., and Proudfoot, A.E. Regulation of protein function by glycosaminoglycans-as exemplified by chemokines. Annu Rev Biochem 74, 385, 2005.
15. Turnbull, J.E., Miller, R.L., Ahmed, Y., Puvirajesinghe, T.M., and Guimond, S.E. Glycomics profiling of heparan sulfate structure and activity. Methods Enzymol 480, 65, 2010.
16. Papy-Garcia, D., Barbier-Chassefiere, V., Rouet, V., Kerros, M., Klochendler, C., Tournaire, M., et al. Nondegradative sulfation of polysaccharides. Synthesis and structure characterization of biologically active heparan sulfate mimetics. Macromolecules 38, 4647, 2005.
17. Colombier, M.L., Lafont, J., Blanquaert, F., Caruelle, J.P., Barritault, D., and Saffar, J.L. A single low dose of RGTA, a new healing agent, hastens wound maturation and enhances bone deposition in rat craniotomy defects. Cells Tissues Organs 164, 131, 1999.
18. Barbier-Chassefiere, V., Garcia-Filipe, S., Yue, X.L., Kerros, M.E., Petit, E., Kern, P., et al. Matrix therapy in regenerative medicine, a new approach to chronic wound healing. J Biomed Mater Res A 90, 641, 2009.
19. Chebbi, C.K., Kichenin, K., Amar, N., Nourry, H., Warnet, J.M., Barritault, D., et al. [Pilot study of a new matrix therapy agent (RGTA OTR4120) in treatment-resistant corneal ulcers and corneal dystrophy]. J Fr Ophtalmol 31, 465, 2008.
20. Ikeda, Y., Charef, S., Ouidja, M.O., Barbier-Chassefiere, V., Sineriz, F., Duchesnay, A., et al. Synthesis and biological activities of a library of glycosaminoglycans mimetic oligosaccharides. Biomaterials 32, 769, 2011.
21. Lafont, J., Blanquaert, F., Colombier, M.L., Barritault, D., Carueelle, J.P., and Saffar, J.L. Kinetic study of early regenerative effects of RGTA11, a heparan sulfate mimetic, in rat craniotomy defects. Calcif Tissue Int 75, 517, 2004.
22. Lafont, J., Baroukh, B., Berdal, A., Colombier, M.L., Barritault, D., Caruelle, J.P., et al. RGTA11, a new healing agent, triggers developmental events during healing of craniotomy defects in adult rats. Growth Factors 16, 23, 1998.
23. Desgranges, P., Barritault, D., Caruelle, J.P., and Tardieu, M. Transmural endothelialization of vascular prostheses is regulated in vitro by Fibroblast Growth Factor 2 and heparan-like molecule. Int J Artif Organs 20, 589, 1997.
24. Desgranges, P., Barbaud, C., Caruelle, J.P., Barritault, D., and Gautron, J. A substituted dextran enhances muscle fiber survival and regeneration in ischemic and denervated rat EDL muscle. FASEB J 13, 761, 1999.
25. Yamauchi, H., Desgranges, P., Lecerf, L., Papy-Garcia, D., Tournaire, M.C., Moczar, M., et al. New agents for the treatment of infarcted myocardium. FASEB J 14, 2133, 2000.
26. Rouet, V., Hamma-Kourbali, Y., Petit, E., Panagopoulou, P., Katsoris, P., Barritault, D., et al. A synthetic glycosaminoglycan mimetic binds vascular endothelial growth factor and modulates angiogenesis. J Biol Chem 23, 280, 32792, 2005.
27. Albanese, P., Caruelle, D., Frescaline, G., Delbe, J., Petit-Cocault, L., Huet, E., et al. Glycosaminoglycan mimeticsinduced mobilization of hematopoietic progenitors and stem cells into mouse peripheral blood: structure/function insights. Exp Hematol 37, 1072, 2009.
28. Nicoletti, A., Bartoloni, A., Sofia, V., Mantella, A., Nsengiyumva, G., Frescaline, G., et al. Epilepsy and toxocariasis: a case-control study in Burundi. Epilepsia 48, 894, 2007.
29. Martelly, I., Singabraya, D., Vandebrouck, A., Papy-Garcia, D., Cognard, C., Raymond, G., et al. Glycosaminoglycan mimetics trigger IP3-dependent intracellular calcium release in myoblasts. Matrix Biol 29, 317, 2010.
30. Courty, J., Dauchel, M.C., Caruelle, D., Perderiset, M., and Barritault, D. Mitogenic properties of a new endothelial cell growth factor related to pleiotrophin. Biochem Biophys Res Commun 15, 180, 145, 1991.
31. Doucet, C., Ernou, I., Zhang, Y., Llense, J.R., Begot, L., Holy, X., et al. Platelet lysates promote mesenchymal stem cell expansion: a safety substitute for animal serum in cell-based therapy applications. J Cell Physiol 205, 228, 2005.
32. Ponte, A.L., Marais, E., Gallay, N., Langonne, A., Delorme, B., Herault, O., et al. The in vitro migration capacity of human bone marrow mesenchymal stem cells: comparison of chemokine and growth factor chemotactic activities. Stem Cells 25, 1737, 2007.
33. Chen, P.R., Chen, M.H., Lin, F.H., and Su, W.Y. Release characteristics and bioactivity of gelatin-tricalcium phosphate membranes covalently immobilized with nerve growth factors. Biomaterials 26, 6579, 2005.
34. Barbosa, I., Garcia, S., Barbier-Chassefiere, V., Caruelle, J.P., Martelly, I., and Papy-Garcia, D. Improved and simple micro assay for sulfated glycosaminoglycans quantification in biological extracts and its use in skin and muscle tissue studies. Glycobiology 13, 647, 2003.
35. Baroukh, B., Cherruau, M., Dobigny, C., Guez, D., and Saffar, J.L. Osteoclasts differentiate from resident precursors in an in vivo model of synchronized resorption: a temporal and spatial study in rats. Bone 27, 627, 2000.
36. Tsai W. Moment-preserving thresholding: a new approach. Comput Vis Graph Image Proc, 29, 377, 1985.
37. Carpentier G. Custom tab stat from results. Available at http://rsb.info.nih.gov/ij/macros/CustomTabStat-FromResults.txt, 2007.
38. Luong-Van, E., Grondahl, L., Song, S., Nurcombe, V., and Cool, S. The in vivo assessment of a novel scaffold containing heparan sulfate for tissue engineering with human mesenchymal stem cells. J Mol Histol 38, 459, 2007.
39. Blanquaert, F., Barritault, D., and Caruelle, J.P. Effects of heparan-like polymers associated with growth factors on osteoblast proliferation and phenotype expression. J Biomed Mater Res 44, 63, 1999.
40. Mestries, P., Alexakis, C., Papy-Garcia, D., Duchesnay, A., Barritault, D., Caruelle, J.P., et al. Specific RGTA increases collagen V expression by cultured aortic smooth muscle cells via activation and protection of transforming growth factorbeta1. Matrix Biol 20, 171, 2001.
41. Alexakis, C., Mestries, P., Garcia, S., Petit, E., Barbier, V., Papy-Garcia, D., et al. Structurally different RGTAs modulate collagen-type expression by cultured aortic smooth muscle cells via different pathways involving fibroblast growth factor-2 or transforming growth factor-beta1. FASEB J 18, 1147, 2004.
42. Escartin, Q., Lallam-Laroye, C., Baroukh, B., Morvan, F.O., Caruelle, J.P., Godeau, G., et al. A new approach to treat tissue destruction in periodontitis with chemically modified dextran polymers. FASEB J 17, 644, 2003.
43. Pieper, J.S., van Wachem, P.B., van Luyn, M.J.A., Brouwer, L.A., Hafmans, T., Veerkamp, J.H., et al. Attachment of glycosaminoglycans to collagenous matrices modulates the tissue response in rats. Biomaterials 21, 1689, 2000.
44. Chen, L., Tredget, E.E., Wu, P.Y., and Wu, Y. Paracrine factors of mesenchymal stem cells recruit macrophages and endothelial lineage cells and enhance wound healing. PLoS One 3, e1886, 2008.
45. Saffar, J.L., Colombier, M.L., and Detienville, R. Bone formation in tricalcium phosphate-filled periodontal intrabony lesions. Histological observations in humans. J Periodontol 61, 209, 1990.
46. Hayman, A.R. Tartrate-resistant acid Phosphatase (TRAP) and the osteoclast/immune cell dichotomy. Autoimmunity 41, 218, 2008.
47. Baud'huin M, Ruiz-Velasco, C., Jego, G., Charrier, C., Gasiunas, N., Gallagher, J., et al. Glycosaminoglycans inhibit the adherence and the spreading of osteoclasts and their precursors: role in osteoclastogenesis and bone resorption. Eur J Cell Biol 90, 49, 2011.
48. Ariyoshi, W., Takahashi, T., Kanno, T., Ichimiya, H., Shinmyouzu, K., Takano, H., et al. Heparin inhibits osteoclastic differentiation and function. J Cell Biochem 15, 103, 1707, 2008.
49. Ling, L., Murali, S., Stein, G.S., van Wijnen, A.J., and Cool, S.M. Glycosaminoglycans modulate RANKL-induced osteoclastogenesis. J Cell Biochem 15, 109, 1222.
50. Irie, A., Takami, M., Kubo, H., Sekino-Suzuki, N., Kasahara, K., and Sanai, Y. Heparin enhances osteoclastic bone resorption by inhibiting osteoprotegerin activity. Bone 41, 165, 2007.
51. Folwarczna, J., Sliwinski, L., Janiec, W., and Pikul, M. Effects of standard heparin and low-molecular-weight heparins on the formation of murine osteoclasts in vitro. Pharmacol Rep 57, 635, 2005.
52. Jackson, R.A., McDonald, M.M., Nurcombe, V., Little, D.G., and Cool, S.M. The use of heparan sulfate to augment fracture repair in a rat fracture model. J Orthop Res 24, 636, 2006.